A phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma

Cancer

Volumn 83, Issue 8, 1998, Pages 1540-1545

  Zimmerman, Todd M ^a   Grinblatt, David L ^a   Malloy, Rebecca ^a   Williams, Stephanie F ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Breast carcinoma; Paclitaxel; Stem cells; Transplantation

Indexed keywords

CYCLOPHOSPHAMIDE; MESNA; PACLITAXEL; THIOTEPA;

ADULT; ARTICLE; BONE MARROW RESCUE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER STAGING; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL PROTOCOL; DOSE RESPONSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; LUNG TOXICITY; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN DISEASES; BREAST NEOPLASMS; CARCINOMA; COHORT STUDIES; CYCLOPHOSPHAMIDE; DIARRHEA; ESOPHAGITIS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGE; HUMANS; INCIDENCE; INFUSIONS, INTRAVENOUS; LUNG DISEASES; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PULMONARY ALVEOLI; REMISSION INDUCTION; STOMATITIS; SURVIVAL RATE; THIOTEPA; TRANSPLANTATION, AUTOLOGOUS;

EID: 0032531897     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19981015)83:8<1540::AID-CNCR8>3.0.CO;2-V     Document Type: Article

References (20)

1. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary therapy for metastatic breast cancer: a randomized trial. J Clin Oncol 1995;13:2483-9.
2. Ayash LJ, Wheeler C, Fairclough D, Scwartz G, Reich E, Warren D, et al. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol 1995;13:2043-9.
3. Grad G, Lane N, Zimmerman T, Bitran J, Mick R, Williams S. High-dose chemotherapy (HDC) and autologous stem cell support in metastatic breast cancer: the University of Chicago experience. Proc Am Soc Clin Oncol 1994;13:73.
4. Rill DR, Santana VM, Roberts VM, Nilson L, Bowman LC, Krance RA, et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994;84:380-3.
5. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Nat Cancer Inst 1991;83:1797-805.
6. Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Nat Acad Sci USA 1993;90:9552-6.
7. Leibmann JE, Cook JA, Lipscultz C, Teague D, Fisher J, Mitchell JB, et al. Cytotoxic studies of paclitaxel (Taxol®) in human tumour cell lines. Br J Cancer 1993;68:1104-9.
8. Georgiadis MS, Russell E, Johnson BE. Prolonging the exposure of human lung cancer cell lines to paclitaxel improves the cytotoxicity [abstract 2028]. Proc Am Assoc Cancer Res 1994;35:341.
9. Wilson WH, Berg S, Bryant G, Wittes RE, Bates S, Fojo A, et al. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol 1994;12:1621-9.
10. Spriggs DR, Tondini C. Taxol administered as a 120 hour infusion. Invest New Drugs 1992;10:275-8.
11. Seidman AD, Hochhauser D, Gollub M, Edelman B, Yao TJ, Hudis CA, et al. Ninety-six hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol 1996;14:1877-84.
12. Brockstein B, Fleming G, Williams SF. Efficacy of paclitaxel after progression following high-dose chemotherapy and autologous stem cell rescue [abstract 205]. Proc Am Soc Clin Oncol 1994;12:103.
13. Williams SF, Mick R, Desser R, Golick J, Beschorner J, Bitran JD. High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer. J Clin Oncol 1989;7: 1824-30.
14. Moormeier JA, Williams SF, Kaminer LS, Garner M, Bitran JD. High-dose tri-alkylator chemotherapy with autologous stem cell rescue in patients with refractory malignancies. J Nat Cancer Inst 1990;82:29-34.
15. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
16. Finn G, Denning D. Transient nephrogenic diabetes insipidus following high-dose cyclophosphamide chemotherapy and autologous bone marrow transplantation. Cancer Treat Rep 1987;71:220-1.
17. Robbins RA, Linder J, Stahl MH, Thompson AB, Haire W, Kessinger A, et al. Diffuse alveolar hemorrhage in autologous bone marrow transplant recipients. Am J Med 1989;87: 511-8.
18. Lefrak EA, Pitha J, Rosenheim S, et al. Adriamycin cardiotoxicity. Cancer Chemother Rep 1975;6(Pt 3):203-8.
19. Bhalla K, Ibrado AM, Tourkina E, Tang C, Mahoney ME, Huang Y. Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia 1993;7:563-8.
20. Stemmer SM, Cagnoni PJ, Shpall EJ, Bearman SI, Matthes S, Dufton C, et al. High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor cell support: a phase I trial. J Clin Oncol 1996;14:1463-72.